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Multi-Scale mapping of vascular pattern for 
development of regenerative and preventive 
therapies targeting diseases dependent on 
microvascular remodeling 
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with VESGEN Software as 
Research Discovery Tool 
at Lewis Field 
Glenn Research Center 
Vascular Alterations, Visual Impairments (VIIP) & Increased 
Intracranial Pressure (ICP), Immunosuppression & Bone Loss:  
NASA-defined risk categories for human space exploration 
and ISS Utilization 
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Vascular pattern may serve as a useful new biomarker principle of complex, multi-scale signaling in pathological, 
physiological angiogenesis and microvascular remodeling. Each angiogenesis stimulator or inhibitor we have analyzed, 
including VEGF, bFGF, TGF-beta1, angiostatin and triamcinolone acetonide, has induced a novel ‘fingerprint’ or 
‘signature’ biomarker vascular pattern that is spatio-temporally unique. Remodeling vasculature thereby provides an 
informative read-out of dominant molecular signaling, when analyzed by innovative, fractal-based VESsel GENeration 
(VESGEN) Analysis software. Using VESGEN to analyze ophthalmic clinical vascular images, we recently introduced a 
potential paradigm shift to the understanding of early-stage progression that suggests new regenerative opportunities 
for human diabetic retinopathy (DR), the major blinding disease for working-aged adults. In a pilot study, we discovered 
that angiogenesis oscillates as a surprising, homeostatic-like regeneration of retinal vessels during early progression of 
DR (IOVS 51(1):498).  Results suggest that the term ‘non-proliferative DR’ may be a misnomer. In new studies, 
normalization of the vasculature will be determined from the response of vascular pattern to therapeutic monitoring and 
treatment. We have mapped and quantified in vivo experimental models of angiogenesis, lymphangiogenesis and 
intravital blood flow from cellular/molecular to higher systems levels that include a murine model of infant retinopathy of 
prematurity (ROP); developing and pathological coronary and placental-like vessel models; progressive intestinal 
inflammation, growing murine tumors, and other pathological, physiological and therapeutically treated tissues of 
transgenic mice and avian embryos. 
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Motivation for Microvascular Quantification 
and Mapping by VESGEN 
1. Cells in Vitro 
4. Humans 
3. Blood Vessels 
1. Cells in Vitro 
2. Avian Eggs 
2. Blood Vessels 3. Blood Vessels 
1. Molecules in Vitro 3. Mouse 
1. Cells in Vitro 
          NASA IR&D to NIH 
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VESGEN 
Mapping and Quantification 
 of Branching Vascular 
Pattern 
  
 
Vascular Trees 
Diabetic Human Retina 
Avian CAM, Yolksac and Mouse/Avian Coronary Vessels 
 
Vascular Networks 
Mouse Intestinal Inflammation, CAM Lymphatic Vessels, Abnormal 
Mouse Corneal Angiogenesis 
 
Vascular Tree-Network Composites 
Mouse Postnatal Retina 
Early Embryonic Coronary Vessels, Juvenile and Adult Leaf Venation 
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Human Retina! Mouse Retina!
!
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Panel to specify 
vessel type 
Main panel 
•! Image specification 
•!Algorithm selection 
•!Process initiation 
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Dynamic Balance Hypothesis	
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Vascular patterning provides integrative, insightful read-out of 
dominant molecular regulators in complex signaling pathways 
of angiogenesis and microvascular remodeling 
 
 
Fractal-Based VESsel GENeration Analysis (VESGEN) Software 
 
Fractal Dimension, Df 
Vessel Number Density, Nv 
Vessel Length Density, Lv 
Vessel Diameter, Dv 
Branchpoint + Endpoint Densities, Brv+Ev 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
Long-Term Translational and Basic Research Hypothesis  
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VESGEN Hypothesis: ?Fingerprint? or ?Signature? Vascular Pattern 
As Integrative Readout of Complex Signaling 
   bFGF as Simple Stimulator 
VEGF as Complexity Factor 
TGF-!1 as Simple Inhibitor 
   but Complex Potentiator 
Arterio Thromb Vasc Biol 20 (2000) 
Microvascular Research 72 (2006) 
Microvascular Research 59 (2000) 
- D?Arcy 
Thompson 
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                 EARLY  Vascular  Nonproliferative DR (NPDR) 
 
                     LATE  Vascular  Proliferative DR (PDR)   
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Current Eye Research 24(4):274-280(2002)	
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Mapping of Progressive Diabetic Retinopathy by VESGEN 
P Parsons-Wingerter, K Radhakrishnan, M B Vickerman, P K Kaiser, IOVS 51(1):498-507 (2010) and in progress 
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Angiogenesis Oscillates with Vascular Dropout  
during Progression of Diabetic Retinopathy 
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P Parsons-Wingerter, K Radhakrishnan, M B Vickerman, P K Kaiser, IOVS 51(1):498-507 (2010) and in progress 
New 
Regeneration 
Opportunity 
 Curr Eye Res 24(4):274 
!
Normal Retina 
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Slight Trend toward Increasing Diameter of Larger Vessels 
during Progression of Diabetic Retinopathy 
 
Parsons, Radhakrishnan, Vickerman & Kaiser, Investigative Ophthalmology & Visual Science 51(1):498-507 (2010) 
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Surprising 
Results 
Grouping by Vascular Remodeling Status (VRS) 
P Parsons-Wingerter, K Radhakrishnan, M B Vickerman, P K Kaiser, IOVS 51(1):498-507 (2010) and in progress 
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Conclusions on Novel Vascular Disease 
Biomarkers during Progression of 
Diabetic Retinopathy 
 
 
 
New, surprising discovery on early-stage angiogenesis during moderate 
NPDR: Does the retina retain the capacity to regenerate itself? 
 
VESGEN as Research Discovery Tool 
Are results important for early-stage regeneration in other inflammatory 
diseases such as diabetic nephropathy and tumors? 
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VESGEN 
 
 
 
 
Vascular Pattern as Informative Biomarker and 
Integrative Readout of Complex Signaling 
Pathways for Angiogenesis, Lymphangiogenesis 
and Other Microvascular Remodeling 
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Human Retina! Mouse Retina!
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: 
                                                                   P P rsons and H-C Reinecker, accepted to Grav Space Biology 
 
VESGEN mapping of vascular networks with GI inflammatory  
progression in experimental mouse DSS model 
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Triamcinolone Acetonide (TA) Steroid Treatment in CAM Vascular Tree 
Reviewed in Anatomical Record 2009; Investigative Ophthalmology & Visual Science 2008!
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P. Kaiser MD, Cole Eye Institute: P. Kaiser MD, Cole Eye Institute: P. Kaiser MD, Cole Eye Institute: 
                               with J Sears & Q Ebrah m (Cole Eye I stitute), from Vickerman et al, Anatomical Record A 292(3), 2009     
 
Vascular Networks in Transgenic Mouse Retina 
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Coronary Vessel Network-to-Tree Transitions 
Vickerman et al, VESGEN Review, Anatomical Record A 292(3), 2009 
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Lymphangiogenic Sprouting: By Filopodial Guidance? 
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Parsons et al, Microvascular Research 167(1):193-211(2005)	
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RESULTS 
A0, a1, a2, a3 
 
Pulsatility comparison 
e5_a2!
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AcerAcer 
Taxonomic/Phylogenetic Identifiers 
 
Botanical rules for leaf vascular patterning 
by branching order   
36 
aEllis, Daly, Hickey et al, Manual of Leaf Architecture, 2009 
bRoth-Nebelsick, Uhl, Mosbrugger, Kerp, Annals of Botany 887:553-566, 2001 
 
Acer argutum 
at Lewis Field 
Glenn Research Center                                                 P Parsons, M Vickerman,A-L Paul, R Ferl submitted to ASGSR 2012 New Orleans                   
 
New VESGEN analysis of leaf venation for Arabidopsis  
with first bioinformatic dimensional analysis  
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ANATOMICAL RECORD 
in press 
TheAnatomicalRecord
Advances in Integrative Anatomy and Evolutionary Biology
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Novel Angiogenesis and 
Vascular Dropout Biomarkers 
by VESGEN 
 
 
 
Potential New Window of Therapeutic Opportunity  
for Early-Stage Regenerative Treatment 
 
Surprising Oscillation of Angiogenesis with Vascular Dropout 
during DR Progression 
• First demonstration of angiogenesis during Moderate NPDR 
• New longitudinal studies with Maria Grant 
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